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Results ANS was initiated in 228 (47%) of patients who met predefined criteria
shown in figure 1. Myeloablative HCT recipients were advised to have an enteral feeding
tube inserted prophylactically at day 1 post HCT. If ETF could not be established then PN
was given. 198 (41%) of subjects never met the criteria for artificial nutrition and
maintained an adequate oral intake. A further 47 (10%) of subjects required ETF for a
median of 12 days to achieve adequate enteral nutrition. There were 148 subjects that
required 4 or more days of PN to achieve adequate nutrition. 127 subjects required PN for
a median of 17 days and 21 required a median of 16 days PN plus 8 days ETF. Episodes
of ANS shorter than 4 days were excluded as likely inappropriate or ineffective.
Table 1: Univariate analyses of nutritional intake group on NRM and acute GvHD
Figure 2: Cumulative incidence for NRM at day 100
Figure 2: Kaplan Meier estimate for NRM at day 100
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Introduction Allogeneic hematopoietic cell transplantation
(HCT) is often associated with poor oral intake and as a result,
nutritional status declines. Although it might seem obvious that optimal
nutrition is likely to improve outcomes of transplantation, there are no
clinical data that directly support this assumption. It is also unclear
whether artificial nutrition support (ANS) should be provided as enteral
tube feeding (ETF) or parenteral nutrition (PN).
Factors significantly 
associated in multivariate 
analyses with NRM, acute 
GvHD grade 2 or above or 
gut acute GvHD of any 
grade are shown in Tables 
2 and 3.
Impact of Nutrition on Non-relapse Mortality and Acute Graft Versus Host 
Disease During Allogeneic Hematopoietic Cell Transplantation for Hematologic 
Malignancies 
Methods A retrospective analysis of 100 day non-relapse
mortality (NRM) and incidence of acute GvHD according to route and
adequacy of nutrition, together with other known prognostic factors,
after allogeneic HCT in a single centre between 2000 and 2014.
Nutritional intake was reviewed from admission to engraftment and
deemed inadequate where an unmet need for ANS was documented.
Exclusion criteria were age < 16 years, non-hematological
malignancy, cord blood or haplo transplant. Myeloablative conditioning
was used in 285 (59%) patients, 272 of whom received a TBI based
regimen. Reduced intensity conditioning was given to 199 (41%)
patients. For the 236 (49%) unrelated donor cell recipients in vivo T-
cell depletion with alemtuzumab was used.
Figure 1: Flow chart for nutritional intake group 
Conclusion Adequate nutrition during allogeneic HCT is associated
with improved 100 day NRM. Adequate EN is associated with significantly
better results for this outcome than adequate PN. Furthermore adequate
EN, predominantly via oral intake may be associated with lower incidence
of acute GvHD when compared to PN, perhaps because of its ability to
maintain gut mucosal integrity and the gastrointestinal tract environment,
including microflora. The significant associations reported here warrant
further research into optimizing enteral nutrition in recipients of HCT.
NRM at 100d
N RR (95% CI) p-value
Nutritional Group
Adequate EN
Adequate PN
Inadequate
242
148
89
1.0
2.9 (1.6 - 5.4)
4.1 (2.2 - 7.2)
<0.001
<0.001
Recipient age (yrs)
< 40
40-60
> 60
212
229
38
1.0
1.9 (1.1 - 3.1)
3.1 (1.5 - 6.8)
0.026
0.004
Previous autograft
< 1
> 0
434
45
1.0
2.4 (1.3 - 4.5) 0.007
Recipient CMV
Negative
Positive
202
277
1.0
1.8 (1.1 - 3.1) 0.027
Acute GVHD grade 2-4 Gut AGVHD any grade 
N OR (95% CI) p-value N OR (95% CI) p-value
Nutritional Group
Adequate EN
Adequate PN
Inadequate (all routes)
231
132
75
1.0
2.0 (1.2 - 3.3)
1.3 (0.7 - 2.2)
0.006
0.38
231
131
75
1.0
1.8  (1.1 - 3.0)
1.3  (0.7 - 2.3)
0.018
0.39
Recipient / Donor Sex
Other combination
Male / Female
353
85
1.0
1.7 (1.0 - 2.7) 0.047
352
85
1.0
1.8 (1.1 - 3.0) 0.025
Conditioning regimen
Myeloablative
Reduced intensity
262
176
1.0
0.5 (0.3 - 0.7)
0.001 262
175
1.0
0.4 (0.3 - 0.7)
<0.001
N NRM at 
100d
% (95%CI)
p-
value
AGVHD grade
N (%)
p-
value
Gut AGVHD
N (%)
p-value
0-1 2-4 No Yes
Overall 484 14.6  (12-18) - 260 (59) 179 (41) - 285 (65) 153 (35) -
Nutritional Intake 
Group
Adequate EN
Adequate PN
Inadequate
245
148
91
8.2 (5-12)
17.1 (12-24)
27.6 (20-38)
<0.001 157 (68)
59 (45)
44 (59)
75 (32)
73 (55)
31 (41)
<0.001 169 (73)
68 (52)
48 (64)
63 (27)
63 (48)
27 (36)
<0.001
The effects of all known 
patient, disease and 
transplant factors were 
studied in univariate 
analyses on NRM and 
acute GvHD, following 
which multivariate analyses 
were performed. Univariate 
effects of  nutritional intake 
group on NRM and acute 
GvHD are shown in Table 1 
and Figure 2. (Univariate 
analyses of other factors 
not shown).  
Table 2: Multivariate analyses of NRM
Table 3: Multivariate analyses of acute GvHD
